Sjögren’s syndrome treatment market to grow to $2.2b by 2024
13 January 2016 | By Victoria White
GlobalData states that this impressive growth will be driven primarily by the launch of Bristol-Myers Squibb’s Orencia from 2021...
List view / Grid view
News
Dolomite aids drug encapsulation studies
12 January 2016 | By Dolomite
A Dolomite microfluidic system is helping Dr Samar Damiati, Assistant Professor in the Biochemistry Department at King Abdulaziz University in Saudi Arabia, perform drug encapsulation studies...
MIURA GO-xHT most powerful clean-up system for dioxins and PCBs
12 January 2016 | By Shimadzu
Less solvent consumption, no cross contamination / Can be combined with Shimadzu’s GCMS-TQ8040 triple quadrupole / Both fulfill new EU 589/2014 regulation on analyzing dioxins and PCBs samples...
FDA grants Priority Review for venetoclax NDA
12 January 2016 | By Victoria White
The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...
Rapidly develop drugs targeting Interleukins with new PathHunter® cell-based assays from DiscoveRx
DiscoveRx Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, announces the expansion of its PathHunter® cell-based assays portfolio with the release of PathHunter Interleukin cell-based assays.
Cytori launches managed access programme for ECCS-50 for scleroderma
12 January 2016 | By Victoria White
ECCS-50 is an autologous, adipose-derived cell therapy produced at the patient’s bedside and administered via a series of hand injections, in a single same-day procedure...
Parkinson’s disease treatment pipeline holds significant potential, says GBI Research
12 January 2016 | By Victoria White
An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets...
Nestlé Health Science and Seres collaborate on Ecobiotics
12 January 2016 | By Victoria White
Nestlé Health Science has signed an exclusive agreement outside the US and Canada for Seres Therapeutics’ Ecobiotics in clostridium difficile infections and inflammatory bowel disease...
Eisai submits MAA for lenvatinib in renal cell carcinoma
12 January 2016 | By Victoria White
Eisai has submitted the MAA to the EMA for the use of lenvatinib in combination with everolimus to treat people with unresectable advanced or metastatic renal cell carcinoma who have received one prior vascular endothelial growth factor targeted therapy...
Tiziana announces development plans for foralumab
11 January 2016 | By Victoria White
The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis...
Shire to acquire Baxalta in $32 billion deal
11 January 2016 | By Victoria White
The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth...
AbbVie initiates Phase 3 studies for pan-genotypic HCV regimen
11 January 2016 | By Victoria White
AbbVie's investigational HCV regimen, combining ABT-493 and ABT-530, will be evaluated in patients with genotypes 1-6 chronic HCV infection...
Incyte and AstraZeneca announce new lung cancer trial collaboration
11 January 2016 | By Victoria White
Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…
Early immune effect of SCIB1 observed by ImmunTraCkeR diagnostic
11 January 2016 | By Victoria White
Cancer vaccine SCIB1 is a DNA ImmunoBody immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions...
Moberg announces positive data for BUPI in oral mucositis
11 January 2016 | By Victoria White
Oral mucositis is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy...
